The HIV diagnostics market was valued at USD 2,600.09 million in 2024 and is expected to reach USD 2,791.20 million by 2025 and USD 5,396.32 million by 2034, exhibiting a CAGR of 7.6% during the forecast period 2025–2034. Advances in molecular diagnostics, high-sensitivity assays, and digital platforms are reshaping how laboratories and healthcare providers detect and manage HIV. This analysis focuses on the technology and laboratory trends influencing B2B investment.

Next-Generation Sequencing and AI-Powered Diagnostic Platforms

Advancements in next-generation sequencing (NGS), AI-powered diagnostic platforms, and high-sensitivity assays are fostering market expansion by improving test accuracy, speed, and accessibility. Evolving global healthcare regulations, approval of innovative diagnostic assays, and streamlined reimbursement frameworks are facilitating wider adoption.

Innovations such as NGS for viral load monitoring, AI-driven diagnostic algorithms, and multiplexed rapid testing kits are reshaping market value and operational efficiency. Companies are investing in scalable diagnostic platforms, microfluidic-based detection methods, and affordable self-testing kits to address evolving epidemiological needs.

In March 2025, bioLytical launched the INSTI Multiplex HIV-1/2 and Syphilis Antibody Test in Australia, delivering results in one minute and enabling simultaneous antibody detection for quicker clinical decisions.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/hiv-diagnostics-market

Product Segment Insights: Consumables and Software

Consumables accounted for the largest product share in 2024 on strong demand for reagents, test kits, and assay consumables across laboratories, hospitals, and point-of-care settings. Frequent replenishment due to high testing volumes and routine screening supports the segment, while technological advancements in multiplex assays, automation-compatible reagents, and high-sensitivity consumables are enhancing commercial adoption.

The software and services segment is expected to register the highest CAGR during the forecast period, supported by the integration of artificial intelligence, machine learning, and cloud-based platforms. Reliance on predictive analytics, digital health records, telehealth, and remote monitoring is accelerating demand for software-enabled HIV testing workflows.

Diagnostic Laboratories Anchor End-Use Demand

Diagnostic laboratories accounted for the largest end-use share in 2024, owing to widespread adoption of advanced technologies, centralized testing models, and stringent regulatory compliance standards. Laboratories serve as primary hubs for high-throughput testing, using PCR-based assays, Western blot confirmatory tests, and immunoassay platforms for accurate viral detection and viral load monitoring. Government-funded screening, accreditation-driven standardization, and the growth of private service providers further strengthen the segment, as does continued need for confirmatory testing and genotypic resistance assays.

Hospitals and clinics are expected to grow significantly, supported by rising testing volumes, integrated care models, PrEP screening, expanding ART clinics, and the adoption of electronic health records and AI-driven decision support. Home settings form the third end-use segment.

Demand is reinforced by epidemiology and funding. In 2022, approximately 31,800 individuals were newly infected with HIV in the US, and the FY 2025 US budget proposal allocates USD 593 million to the Ending the HIV Epidemic initiative, increasing the burden on efficient, high-throughput testing infrastructure.

Regional and Competitive Landscape of the HIV Diagnostics Market

North America held the largest share in 2024, while Asia Pacific is expected to witness the highest CAGR. The competitive landscape features global leaders and regional players competing through innovation, partnerships, and expansion. Key players include Abbott; Apogee Flow Systems; BD; Beckman Coulter, Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Janssen Global Services, LLC; Merck & Co. Inc.; Mylan N.V.; QIAGEN; Siemens Healthcare GmbH; Sysmex Europe SE; and VIIV Healthcare.

Leading companies leverage advanced R&D capabilities, AI-driven automation, and next-generation molecular diagnostics to improve test accuracy, speed, and accessibility. Roche develops both drugs and diagnostic tools, serving hospitals, commercial laboratories, and researchers. Gilead Sciences, known for antiviral therapies, achieved its first major success in 1996 with the HIV diagnostic  treatment Viread. Strategic investments, mergers and acquisitions, and cross-industry collaborations remain central, although high cost is a noted restraint.

More Trending Latest Reports By Polaris Market Research:

listing-top-10-companies-in-the-titanium-dioxide-market-2025

aerospace-parts-manufacturing-market

analyzing-top-15-companies-driving-growth-in-single-use-bioreactor-market-in-2025

platelet-rich-plasma-market

gpu-as-a-service-market

point-of-care-poc-diagnostics-market

global-industrial-fasteners-market

plastic-compounding-market

flame-retardant-apparel-market